March 20, 2017

Verseon Corporation (“Verseon” or the “Company”)

Verseon to showcase low bleeding risk anticoagulation candidates at BIO-Europe Spring

FREMONT, Calif.—Tomorrow, Dr. David Kita, Vice President of R&D at Verseon, will present preclinical results on the Company’s novel class of potent, highly selective direct thrombin inhibitors at the 2017 BIO-Europe Spring conference in Barcelona.

Verseon has developed multiple, chemically diverse drug candidates that show efficacy comparable to the NOACs in preclinical models of arterial and venous thromboembolism, but do not disrupt platelet function. This distinguishing feature provides a biological explanation for the reduced bleeding risk of the Verseon inhibitors observed in preclinical testing.

The presentation will also cover Verseon’s first development candidate for clinical trials. The candidate has pharmacokinetics suitable for oral dosing and is well tolerated even at high doses in single and repeat dosing studies. Furthermore, this development candidate exhibits very low renal clearance in preclinical studies, a highly desirable property for patients with impaired kidney function.

“Our drug candidates effectively inhibit thrombosis while preserving hemostasis, striking a balance that is lacking in current anticoagulants. This leads to the remarkably safe bleeding profile of our candidates that will make them best-in-class therapeutics,” said Dr. Kita.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.

-Ends-

For further information please contact

Verseon Corporation www.verseon.com
Arthur Shmurun / Amy Thai +1 (510) 225 9000
Cenkos Securities (NOMAD and Joint Broker)
Neil McDonald / Beth McKiernan +44 (0) 20 7397 8900
Cantor Fitzgerald Europe (Joint Broker)
Marc Milmo / Phil Davies / Callum Butterfield +44 (0) 20 7894 7000
Mirabaud Securities LLP (Joint Broker)
Peter Krens +44 (0) 20 7321 2508

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, WHICH ARE GENERALLY STATEMENTS THAT ARE NOT HISTORICAL FACTS. FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE WORDS "EXPECTS," "ANTICIPATES," "BELIEVES," "INTENDS," "ESTIMATES," "PLANS," "WILL," “OUTLOOK” AND SIMILAR EXPRESSIONS. FORWARD-LOOKING STATEMENTS ARE BASED ON MANAGEMENT’S CURRENT PLANS, ESTIMATES, ASSUMPTIONS AND PROJECTIONS, AND SPEAK ONLY AS OF THE DATE THEY ARE MADE. WE UNDERTAKE NO OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENT IN LIGHT OF NEW INFORMATION OR FUTURE EVENTS, EXCEPT AS OTHERWISE REQUIRED BY LAW. FORWARD-LOOKING STATEMENTS INVOLVE INHERENT RISKS AND UNCERTAINTIES, MOST OF WHICH ARE DIFFICULT TO PREDICT AND ARE GENERALLY BEYOND OUR CONTROL. ACTUAL RESULTS OR OUTCOMES MAY DIFFER MATERIALLY FROM THOSE IMPLIED BY THE FORWARD-LOOKING STATEMENTS AS A RESULT OF THE IMPACT OF A NUMBER OF FACTORS.

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods

 

Drug Programs

Three different therapeutic areas, all with unmet (or poorly met) medical needs